Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias-Reference-Cited by-同舟云学术

Informative Censoring of Progression-Free Survival Data in the TROPiCS-02 Trial: An Unrecognized Bias

Published:2023-03-10 Issue:8 Volume:41 Page:1629-1630
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Li Guo-Fu¹^ORCID,Qiao Yu-Wei¹,Guan Ai-Jia¹^ORCID,Yu Guo¹^ORCID

Affiliation:

1. Guo-Fu Li, PhD, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China, Subei People's Hospital, Yangzhou, China; Yu-Wei Qiao, BM, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China; Ai-Jia Guan, BM, First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China; and Guo Yu, PhD, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu,...

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.22.02234

Reference6 articles.

1. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

2. Informative censoring — a neglected cause of bias in oncology trials

3. Informative censoring of surrogate end-point data in phase 3 oncology trials

4. Comparison of 3 Randomized Clinical Trials of Frontline Therapies for Malignant Pleural Mesothelioma

5. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overall Survival Benefit with Sacituzumab Govitecan in Metastatic Breast Cancer: A Post Hoc Interaction Analyses of a Randomized Controlled Trail;Clinical Drug Investigation;2024-06

2. The Effects of Anlotinib Combined with Chemotherapy following Progression on Cyclin‐Dependent Kinase 4/6 Inhibitor in Hormone Receptor‐Positive Metastatic Breast Cancer;The Breast Journal;2024-01

3. Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA);The Breast;2023-12

4. Sacituzumab govitecan in HR+ and HER2- metastatic breast cancer: for all or for some?;The Lancet;2023-10

5. Reply to G.-F. Li et al, K. Altundag, and N. SG et al;Journal of Clinical Oncology;2023-03-10